Cerebrospinal fluid biomarker for Parkinson's disease: An overview

被引:32
作者
Maass, Fabian [1 ]
Schulz, Isabel [2 ]
Lingor, Paul [4 ]
Mollenhauer, Brit [1 ,3 ]
Baehr, Mathias [1 ]
机构
[1] Univ Med Ctr, Dept Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany
[2] Univ Southampton, Fac Med, 12 Univ Rd, Southampton SO17 1BJ, Hants, England
[3] Paracelsus Elena Klin, Klin Str 16, D-24128 Kassel, Germany
[4] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, Ismaninger Str 22, D-81675 Munich, Germany
关键词
Parkinson's disease; Biomarker; CSF; ALPHA-SYNUCLEIN; CSF BIOMARKERS; BIOLOGICAL-FLUIDS; AMYLOID-BETA; T-TAU; PROGRESSION; NEURODEGENERATION; DIAGNOSIS; MARKERS; PROTEIN;
D O I
10.1016/j.mcn.2018.12.005
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful biomarkers for early and differential diagnosis, disease monitoring or subtype characterization. Up to now, no biofluid biomarker has entered the daily clinical routine. Cerebrospinal fluid (CSF) is often used as a source for biomarker development in different neurological disorders because it reflects changes in central-nervous system homeostasis. This review article gives an overview about different biomarker approaches in PD, mainly focusing on CSF analyses. Current state and future perspectives regarding classical protein markers like alpha-synuclein, but also different "omics" techniques are described. In conclusion, technical advancements in the field already yielded promising results, but further multicenter trials with well-defined cohorts, standardized protocols and integrated data analysis of different modalities are needed before successful translation into routine clinical application.
引用
收藏
页码:60 / 66
页数:7
相关论文
共 101 条
[1]  
Abdi F, 2006, J ALZHEIMERS DIS, V9, P293
[2]   Low clinical diagnostic accuracy of early vs advanced Parkinson disease Clinicopathologic study [J].
Adler, Charles H. ;
Beach, Thomas G. ;
Hentz, Joseph G. ;
Shill, Holly A. ;
Caviness, John N. ;
Driver-Dunckley, Erika ;
Sabbagh, Marwan N. ;
Sue, Lucia I. ;
Jacobson, Sandra A. ;
Belden, Christine M. ;
Dugger, Brittany N. .
NEUROLOGY, 2014, 83 (05) :406-412
[3]   Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease [J].
Alves, Guido ;
Pedersen, Kenn Freddy ;
Bloem, Bastiaan R. ;
Blennow, Kaj ;
Zetterberg, Henrik ;
Borm, George F. ;
Dalaker, Turi O. ;
Beyer, Mona K. ;
Aarsland, Dag ;
Andreasson, Ulf ;
Lange, Johannes ;
Tysnes, Ole-Bjorn ;
Zivadinov, Robert ;
Larsen, Jan Petter .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (05) :537-543
[4]  
Anderson J. P, 2006, PHOSPHORYLATION SER, DOI [10.1074/jbc.M600933200, DOI 10.1074/JBC.M600933200]
[5]   Alpha-Synuclein as a Biomarker for Parkinson's Disease [J].
Atik, Anzari ;
Stewart, Tessandra ;
Zhang, Jing .
BRAIN PATHOLOGY, 2016, 26 (03) :410-418
[6]   Early predictors of mortality in parkinsonism and Parkinson disease A population-based study [J].
Backstrom, David ;
Granasen, Gabriel ;
Domellof, Magdalena Eriksson ;
Linder, Jan ;
Mo, Susanna Jakobson ;
Riklund, Katrine ;
Zetterberg, Henrik ;
Blennow, Kaj ;
Forsgren, Lars .
NEUROLOGY, 2018, 91 (22) :E2045-E2056
[7]   Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease [J].
Backstrom, David C. ;
Domellof, Magdalena Eriksson ;
Linder, Jan ;
Olsson, Bob ;
Ohrfelt, Annika ;
Trupp, Miles ;
Zetterberg, Henrik ;
Blennow, Kaj ;
Forsgren, Lars .
JAMA NEUROLOGY, 2015, 72 (10) :1175-1182
[8]  
Bernheimer H, 1966, Wien Klin Wochenschr, V78, P417
[9]   A review of genome-wide transcriptomics studies in Parkinson's disease [J].
Borrageiro, Genevie ;
Haylett, William ;
Seedat, Soraya ;
Kuivaniemi, Helena ;
Bardien, Soraya .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2018, 47 (01) :1-16
[10]   Reconciling Braak's model of Parkinson's disease with a prion-like spread of alpha synuclein pathology [J].
Brooks, Patricia L. ;
Visanji, Naomi P. ;
Hazrati, Lili-Naz ;
Lang, Anthony E. .
BASAL GANGLIA, 2012, 2 (04) :167-170